国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (3): 206-209.doi: 10.3760/cma.j.issn.1673422X.2015.03.012

• 综述 • 上一篇    下一篇

表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的耐药机制

柳韵,冯继锋,焉兆玥   

  1. 210009 南京医科大学附属江苏省肿瘤医院肿瘤内科（柳韵、冯继锋）；苏州大学附属第一医院血液科 江苏省血液研究所（焉兆玥）
  • 出版日期:2015-03-08 发布日期:2015-01-29
  • 通讯作者: 冯继锋，Email: medfjif@sina.com E-mail:medfjif@sina.com

Research progression on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer

Liu Yun, Feng Jifeng, Yan Zhaoyue   

  1. Department of Medical Oncology, Affiliated Jiangsu Cancer Hospital of Nanjing Medical University, Nanjing 210009, China
  • Online:2015-03-08 Published:2015-01-29
  • Contact: Feng Jifeng E-mail:medfjif@sina.com
  • Supported by:

    国家自然科学基金（81372396）

PDF

1388

摘要： 表皮生长因子受体酪氨酸激酶抑制剂（EGFRTKI）在非小细胞肺癌的治疗中具有重要地位，但有研究发现患者会对EGFRTKI产生原发性耐药或获得性耐药。目前发现获得性耐药的多种机制最终都导致表皮生长因子受体的下游信号通路被重新激活。肝X受体激动剂对表皮生长因子受体最重要的下游通路PI3K-Akt-NF-κB的多个主要环节均有不同程度的抑制作用，有望逆转EGFRTKI的继发耐药。

关键词: 受体, 表皮生长因子, 癌, 非小细胞肺, 抗药性, 肝X受体

Abstract: EGFRTKI plays an important role in the treatment of nonsmallcell lung cancer. However, some researchers find that there are still some patients with primary or acquired resistance to EGFRTKI. The present known mechanisms of acquired drug resistance finally lead to the reactivation EGFR downstream signaling pathways. Liver X receptor agonist has inhibition function to several critical steps of EGFR downstream signaling pathways PI3KAktNFκB, which makes it possible to overcome the drug resistance.

Key words: Receptor, epidermal growth factor, Carcinoma, nonsmallcell lung, Drug resistance, Liver X receptor